title: Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.
abstract: OBJECTIVE
  In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
  
  
  METHODS
  From 1994 through 2004, 418 consecutive patients with NSCLC underwent complete resection; 138 experienced a postoperative recurrence by December 2005. Of those, we reviewed 93 patients with only distant metastases for clinicopathological information, treatment modality, and survival.
  
  
  RESULTS
  For the 93 patients with distant metastasis alone, the 2- and 5-year survival rates after recurrence were 43.9% and 38.7%, respectively. Of those patients, 44 first received local treatment, including radiotherapy in 31 and a surgical resection in 13. Their recurrent disease (oligometastases) was limited with the potential to be controlled with local treatment. The targeted metastatic organs were brain in 14 patients, bone in 14, lungs in 12, and other organs in 4. Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
  
  
  CONCLUSIONS
  Local therapy such as radiotherapy and surgery, might be considered first-line treatment in patients with postoperative oligometastatic recurrence, especially those with a DFI ≥ 1 year.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. tokujiro@surg2.med.kyushu-u.ac.jp
authors.forename: Tokujiro
authors.initials: T
authors.lastname: Yano
authors.forename: Akira
authors.initials: A
authors.lastname: Haro
authors.forename: Tsukihisa
authors.initials: T
authors.lastname: Yoshida
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Morodomi
authors.forename: Kensaku
authors.initials: K
authors.lastname: Ito
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Shikada
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Shoji
authors.forename: Riichiroh
authors.initials: R
authors.lastname: Maruyama
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D009367:Neoplasm Staging; D011184:Postoperative Period; D015996:Survival Rate; D016896:Treatment Outcome